These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 28011050)

  • 1. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
    Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
    Dietz A; Wichmann G; Kuhnt T; Pfreundner L; Hagen R; Scheich M; Kölbl O; Hautmann MG; Strutz J; Schreiber F; Bockmühl U; Schilling V; Feyer P; de Wit M; Maschmeyer G; Jungehülsing M; Schroeder U; Wollenberg B; Sittel C; Münter M; Lenarz T; Klussmann JP; Guntinas-Lichius O; Rudack C; Eich HT; Foerg T; Preyer S; Westhofen M; Welkoborsky HJ; Esser D; Thurnher D; Remmert S; Sudhoff H; Görner M; Bünzel J; Budach V; Held S; Knödler M; Lordick F; Wiegand S; Vogel K; Boehm A; Flentje M; Keilholz U
    Ann Oncol; 2018 Oct; 29(10):2105-2114. PubMed ID: 30412221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
    Janoray G; Pointreau Y; Alfonsi M; Sire C; Geoffrois L; de Raucourt D; Bardet E; Calais MH; Garaud P; Calais G
    Eur J Cancer; 2020 Jul; 133():86-93. PubMed ID: 32454417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
    Popovtzer A; Burnstein H; Stemmer S; Limon D; Hili O; Bachar G; Sopov V; Feinmesser R; Groshar D; Shvero J
    Head Neck; 2017 Feb; 39(2):227-233. PubMed ID: 27556178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and
    Wichmann G; Krüger A; Boehm A; Kolb M; Hofer M; Fischer M; Müller S; Purz S; Stumpp P; Sabri O; Dietz A; Kluge R
    Eur J Cancer; 2017 Feb; 72():144-155. PubMed ID: 28033526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.
    Bozec A; Benezery K; Ettaiche M; Chamorey E; Vandersteen C; Dassonville O; Poissonnet G; Riss JC; Hannoun-Lévi JM; Chand ME; Leysalle A; Saada E; Guigay J; Sudaka A; Demard F; Santini J; Peyrade F
    Eur Arch Otorhinolaryngol; 2016 Oct; 273(10):3299-306. PubMed ID: 26858198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
    Guadagnolo BA; Haddad RI; Posner MR; Weeks L; Wirth LJ; Norris CM; Sullivan CA; Goguen L; Busse PM; Tishler R
    Am J Clin Oncol; 2005 Aug; 28(4):371-8. PubMed ID: 16062079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study.
    Su X; He C; Tang T; Chen W; Li Z; Chen Y; Yang A
    Am J Otolaryngol; 2017; 38(1):52-56. PubMed ID: 27825651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy in head and neck cancers: Results and controversies.
    Gau M; Karabajakian A; Reverdy T; Neidhardt EM; Fayette J
    Oral Oncol; 2019 Aug; 95():164-169. PubMed ID: 31345386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.
    Lefebvre JL; Pointreau Y; Rolland F; Alfonsi M; Baudoux A; Sire C; de Raucourt D; Malard O; Degardin M; Tuchais C; Blot E; Rives M; Reyt E; Tourani JM; Geoffrois L; Peyrade F; Guichard F; Chevalier D; Babin E; Lang P; Janot F; Calais G; Garaud P; Bardet E
    J Clin Oncol; 2013 Mar; 31(7):853-9. PubMed ID: 23341517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
    Pointreau Y; Garaud P; Chapet S; Sire C; Tuchais C; Tortochaux J; Faivre S; Guerrif S; Alfonsi M; Calais G
    J Natl Cancer Inst; 2009 Apr; 101(7):498-506. PubMed ID: 19318632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
    Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
    Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
    Ock CY; Keam B; Kim TM; Han DH; Won TB; Lee SH; Hah JH; Kwon TK; Kim DW; Kim DY; Rhee CS; Wu HG; Sung MW; Heo DS
    Korean J Intern Med; 2016 May; 31(3):570-8. PubMed ID: 26976150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
    Cmelak AJ; Li S; Goldwasser MA; Murphy B; Cannon M; Pinto H; Rosenthal DI; Gillison M; Forastiere AA
    J Clin Oncol; 2007 Sep; 25(25):3971-7. PubMed ID: 17761982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
    Forastiere AA; Zhang Q; Weber RS; Maor MH; Goepfert H; Pajak TF; Morrison W; Glisson B; Trotti A; Ridge JA; Thorstad W; Wagner H; Ensley JF; Cooper JS
    J Clin Oncol; 2013 Mar; 31(7):845-52. PubMed ID: 23182993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term update of the 24954 EORTC phase III trial on larynx preservation.
    Henriques De Figueiredo B; Fortpied C; Menis J; Lefebvre JL; Barzan L; de Raucourt D; Geoffrois L; Giurgea L; Hupperets P; Leemans CR; Licitra L; Rolland F; Tesselaar M; Vermorken JB; Grégoire V;
    Eur J Cancer; 2016 Sep; 65():109-12. PubMed ID: 27494036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma.
    Majem M; Mesia R; Mañós M; Gomez J; Galiana R; Cardenal F; Juan A; Montes A; Perez FJ; Nogues J; Llluch JR
    Laryngoscope; 2006 Sep; 116(9):1651-6. PubMed ID: 16954998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.